Sandbox: HCL therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{familytree/start |summary=PE diagnosis Algorithm.}} | {{familytree/start |summary=PE diagnosis Algorithm.}} | ||
{{familytree | | | | | | A02 | | | | | |A02=<div style="width: 10em; padding:0.2em;">'''Initial patients evaluation'''</div>}} | {{familytree | | | | | | A02 | | | | | |A02=<div style="width: 10em; padding:0.2em;">'''Initial patients evaluation'''</div>}} | ||
{{familytree|boxstyle= border-top: 0px;| | | | | | A01 | | | | | | |A01=<div style="width: 15em; padding:1em;">History<br>Physical examination<br>Complete blood count</div>}} | {{familytree|boxstyle= border-top: 0px;| | | | | | A01 | | | | | | |A01=<div style="width: 15em; padding:1em;text-align:center">History<br>Physical examination<br>Complete blood count</div>}} | ||
{{familytree | | | | | | |!| | | | | | | | | | | | }} | {{familytree | | | | | | |!| | | | | | | | | | | | }} | ||
{{familytree | | | | | | |!| | | | | | | | | | | | }} | {{familytree | | | | | | |!| | | | | | | | | | | | }} | ||
{{familytree | | | | |,|-|^|-|.| | | | | | }} | {{familytree | | | | |,|-|^|-|.| | | | | | }} | ||
{{familytree | | | | B02 | |B01| | |B02=<div style="width: 10em; padding:1em;">'''Asymptomatic patients with no therapeutic indications'''</div>|B01=<div style="width: 15em; padding:1em;">'''Symptomatic patients or evidence of therapeutic indications '''</div>}} | {{familytree | | | | B02 | |B01| | |B02=<div style="width: 10em; padding:1em;text-align:center">'''Asymptomatic patients with no therapeutic indications'''</div>|B01=<div style="width: 15em; padding:1em;text-align:center">'''Symptomatic patients or evidence of therapeutic indications '''</div>}} | ||
{{familytree | | | | |!| | | |!| | | | }} | {{familytree | | | | |!| | | |!| | | | }} | ||
{{familytree | | | | |!| | | |!| | | | }} | {{familytree | | | | |!| | | |!| | | | }} | ||
{{familytree | | | | C02 | | C01| | |C01=<div style="width: 10em; padding:1em;"> | {{familytree | | | | C02 | | C01| | |C01=<div style="width: 10em; padding:1em;"> | ||
'''[[Cladribine]]'''<br> | '''[[Cladribine]]'''<br> | ||
'''[[Pentostatin]]'''</div>|C02=<div style="width: 15em; padding:1em;">'''Patients managed by observation and close follow-up'''</div>}} | '''[[Pentostatin]]'''</div>|C02=<div style="width: 15em; padding:1em;text-align:center">'''Patients managed by observation and close follow-up'''</div>}} | ||
{{familytree | | | | | | | | |!| | | | | | | | | | | | | }} | {{familytree | | | | | | | | |!| | | | | | | | | | | | | }} | ||
{{familytree | | | | | | |,|-|^|-|.| | | | | | | | | | | }} | {{familytree | | | | | | |,|-|^|-|.| | | | | | | | | | | }} | ||
{{familytree | | | | | | D02 | | D01 | | | | | | | | | |D01=<div style="width: 15em; padding:1em;">'''No evidence of complete response'''</div>|D02=<div style="width: 15em; padding:1em;">'''Complete response'''</div>}} | {{familytree | | | | | | D02 | | D01 | | | | | | | | | |D01=<div style="width: 15em; padding:1em;text-align:center">'''No evidence of complete response'''</div>|D02=<div style="width: 15em; padding:1em;text-align:center">'''Complete response'''</div>}} | ||
{{familytree | | | | | | |!| | | |!| | | | | | | | | | | }} | {{familytree | | | | | | |!| | | |!| | | | | | | | | | | }} | ||
{{familytree | | | | | | |!| | | |!| | | | | | | | | | | }} | {{familytree | | | | | | |!| | | |!| | | | | | | | | | | }} | ||
| Line 20: | Line 20: | ||
'''[[Retuximab]] alone'''<br> | '''[[Retuximab]] alone'''<br> | ||
'''[[Interferon alpha]] alone'''<br> | '''[[Interferon alpha]] alone'''<br> | ||
'''Alternative purine analogue {{withorwithout}} rituximab'''</div>|E02=<div style="width: 13em; padding:1em;">'''Follow-up and close observation'''</div>}} | '''Alternative purine analogue {{withorwithout}} rituximab'''</div>|E02=<div style="width: 13em; padding:1em;text-align:center">'''Follow-up and close observation'''</div>}} | ||
{{familytree | | | | | | |!| | | |!| | | | | | | | | | | }} | {{familytree | | | | | | |!| | | |!| | | | | | | | | | | }} | ||
{{familytree | | | | | | |!| | | |!| | | | | | | | | | | }} | {{familytree | | | | | | |!| | | |!| | | | | | | | | | | }} | ||
{{familytree | | | | | | E02 | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align:center">'''No evidence of complete response'''</div>|E02=<div style="width: 13em; padding:1em;">''' | {{familytree | | | | | | E02 | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align:center">'''No evidence of complete response'''</div>|E02=<div style="width: 13em; padding:1em;"> | ||
'''Relapse after one year: same initial purine analogue ± rituximab'''<br> | |||
'''Relapse before one year: alternative purine analogue ± rituximab'''</div>}} | |||
{{familytree | | | | | | | | | | |!| | | | | | | | | | | }} | {{familytree | | | | | | | | | | |!| | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | | |!| | | | | | | | | | | }} | {{familytree | | | | | | | | | | |!| | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align: | {{familytree | | | | | | | | | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align:lef">'''[[Vemurafenib]]'''</div>}} | ||
{{familytree/end}} | {{familytree/end}} | ||
<br> | <br> | ||
Latest revision as of 02:16, 30 October 2015
Initial patients evaluation | |||||||||||||||||||||||||||||||||||||||||||
History Physical examination Complete blood count | |||||||||||||||||||||||||||||||||||||||||||
Asymptomatic patients with no therapeutic indications | Symptomatic patients or evidence of therapeutic indications | ||||||||||||||||||||||||||||||||||||||||||
Patients managed by observation and close follow-up | |||||||||||||||||||||||||||||||||||||||||||
Complete response | No evidence of complete response | ||||||||||||||||||||||||||||||||||||||||||
Follow-up and close observation | Retuximab alone | ||||||||||||||||||||||||||||||||||||||||||
Relapse after one year: same initial purine analogue ± rituximab | No evidence of complete response | ||||||||||||||||||||||||||||||||||||||||||